Cancer drug resistance: an evolving paradigm

By C. Holohan, S. V. Schaeybroeck, D. Longley, P. Johnston. Nature Reviews. Cancer, 2013

4,374 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/cdfdf9722428afa34f8b5d31f5be51b25b787695

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset (2015, neutral): “Furthermore, given the heterogeneous response of patients to cancer therapies and the frequent development of drug resistance, it is imperative to identify the molecular settings in which small molecules or combinations of small molecules lead to durable patient responses (2, 3).”
Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning (2018, background): “, 2016), tissue inhibitors of metalloproteinases (TIMPs) (DeClerck, 2000) and various cytokines and growth factors (Holohan et al., 2013), all have been shown to alter drug response and mediate drug resistance in cancer.”
The tumor microenvironment underlies acquired resistance to CSF1R inhibition in gliomas (2016, background): “Although classical mechanisms of tumor cell– intrinsic resistance to cytotoxic and targeted agents have been well-defined—including aberrant drug metabolism and transport, drug target mutation, and activation of alternative survival pathways (47)—it still remains unclear whether resistance to TME-di”
Machine learning approaches to drug response prediction: challenges and recent progress (2020, methodology): “Readers are referred to work by Holohan et al. 51 , Housman et al. 59 , and Malhotra and Perry 61 for a comprehensive discussion on this topic.”
Drug resistance and combating drug resistance in cancer (2019, background): “Despite the achievements made in treating cancers during the past decades, resistance to classical chemotherapeutic agents and/or novel targeted drugs continue to be a major problem in cancer therapies and responsible for most relapses, one of the major causes of death in cancer([3-7]).”
Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles (2017, background): “Drug resistance and side effect have been considered as the main reasons for the failure of cancer chemotherapy [2,3].”
Drug Resistance in Cancer: An Overview (2014, background): “These examples and the roles of apoptosis and autophagy in cancer drug resistance have been extensively discussed elsewhere [14].”